These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26761341)

  • 1. Fluad--an adjuvanted seasonal influenza vaccine for older adults.
    Med Lett Drugs Ther; 2016 Jan; 58(1486):8. PubMed ID: 26761341
    [No Abstract]   [Full Text] [Related]  

  • 2. Influenza vaccine for 2015-2016.
    Med Lett Drugs Ther; 2015 Sep; 57(1477):125-7. PubMed ID: 26353043
    [No Abstract]   [Full Text] [Related]  

  • 3. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
    O'Hagan DT
    Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza vaccine efficacy trials: a simulation approach to understand failures from the past.
    Benoit A; Legrand C; Dewé W
    Pharm Stat; 2015; 14(4):294-301. PubMed ID: 25924929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dynamical model for influenza under seasonal variables.
    Taherian M; Toomanian M; Molaei M
    Theor Biol Forum; 2014; 107(1-2):151-62. PubMed ID: 25936220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing vaccine efficacy in influenza clinical trials: challenges and difficulties.
    Dewe W; Benoit A; Legrand C
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):403-11. PubMed ID: 23927668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter from the editor.
    Ellis R; Riedmann EM
    Hum Vaccin Immunother; 2012 Jan; 8(1):1. PubMed ID: 22251991
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
    J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
    Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Problems of large scale influenza vaccine trials.
    Smith JW
    J Antimicrob Chemother; 1975 Dec; 1(4 Suppl):19-26. PubMed ID: 1206028
    [No Abstract]   [Full Text] [Related]  

  • 11. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli G; Groth N; Del Giudice G
    Hum Vaccin Immunother; 2012 Feb; 8(2):216-27. PubMed ID: 22426371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza virus vaccine live intranasal (Aviron). FluMist, influenza vaccine live intranasal.
    Drugs R D; 1999 Sep; 2(3):204-7. PubMed ID: 10641229
    [No Abstract]   [Full Text] [Related]  

  • 13. Influenza and influenza vaccination.
    Goodman RA; Hinman AR; Nolan TF; Brandling-Bennett AD
    Am Fam Physician; 1980 Jan; 21(1):101-5. PubMed ID: 7350730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges of Making Effective Influenza Vaccines.
    Gouma S; Anderson EM; Hensley SE
    Annu Rev Virol; 2020 Sep; 7(1):495-512. PubMed ID: 32392457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza virus surveillance, vaccine strain selection, and manufacture.
    Stöhr K; Bucher D; Colgate T; Wood J
    Methods Mol Biol; 2012; 865():147-62. PubMed ID: 22528158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
    Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A
    Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deaths after Fluad flu vaccine and the epidemic of panic in Italy.
    Signorelli C; Odone A; Conversano M; Bonanni P
    BMJ; 2015 Jan; 350():h116. PubMed ID: 25589037
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009.
    Moro PL; Broder K; Zheteyeva Y; Walton K; Rohan P; Sutherland A; Guh A; Haber P; Destefano F; Vellozzi C
    Am J Obstet Gynecol; 2011 Feb; 204(2):146.e1-7. PubMed ID: 20965490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
    Nolan T; Bravo L; Ceballos A; Mitha E; Gray G; Quiambao B; Patel SS; Bizjajeva S; Bock H; Nazaire-Bermal N; Forleo-Neto E; Cioppa GD; Narasimhan V
    Vaccine; 2014 Oct; 32(46):6146-56. PubMed ID: 25223266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza vaccines: an Asia-Pacific perspective.
    Jennings LC
    Influenza Other Respir Viruses; 2013 Nov; 7 Suppl 3(Suppl 3):44-51. PubMed ID: 24215381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.